Glaucoma in the far-sighted, who have smaller-than-normal anterior chambers, making physical contact between the iris and trabecular meshwork more likely. Normal-tension glaucoma (also "NTG", "low-tension glaucoma", "normal-pressure glaucoma") is a condition where the optic nerve is damaged although intraocular pressure (IOP) is in the normal range (12-22mm Hg). Individuals with a family history of NTG, those of Japanese ancestry, and those with a history of systemic heart disease are at higher than average risk of developing NTG. The cause of NTG is unknown. Secondary glaucoma refers to any case in which another disease, trauma, drug or procedure causes increased eye pressure,
Minimally invasive glaucoma surgery vision and take extra time to recover. The surgery site can scar over time and the pressure can go back up. In early 2014, the NeoMedix received a warning letter from FDA regarding marketing practices. Minimally invasive glaucoma surgery Micro-invasive glaucoma surgery (MIGS) is the latest advance in surgical treatment for glaucoma, which aims to reduce intraocular pressure by either increasing outflow of aqueous humor or reducing its production. MIGS comprises a group of surgical procedures which share common features. MIGS procedures involve a minimally invasive approach, often with small cuts or micro-incisions through the cornea that causes the least